__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Resources for HCPs to support the use of ILARIS® (canakinumab) in day-to-day practice.
Watch the video below to learn how ILARIS Homecare can support you and your patients*.
Indications
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:1
- CAPS, including:
- Muckle-Wells syndrome (MWS)
- Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
- Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
- TRAPS
- HIDS/MKD
- FMF
- ILARIS should be given in combination with colchicine, if appropriate.
Ilaris is also indicated in patients who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, for the treatment of:
Still’s disease, including:
- Adult-onset Still’s disease (AOSD)
- Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older
- ILARIS can be given as monotherapy or in combination with methotrexate
AOSD, adult-onset Still’s disease; CAPS, cryopyrin-associated periodic syndromes; CINCA, chronic infantile neurological, cutaneous, articular syndrome; FCAS, familial cold autoinflammatory syndrome; FCU, familial cold urticaria; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease; NSAID, non-steroidal anti-inflammatory drug; SJIA, systemic juvenile idiopathic arthritis; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.
*If the physician determines that it is appropriate (and with medical follow-up as necessary), patients or their caregivers may inject canakinumab after proper training in the correct injection technique.
Reference
- ILARIS® (canakinumab) Summary of Product Characteristics.
- Pharmaxo How We Work. Available at: https://pharmaxo.com/for-patients/how-we-work/ [Accessed October 2022].
- Pharmaxo Our Services. Available at: https://pharmaxo.com/for-patients/services/ [Accessed October 2022].
- Pharmaxo Supporting Taking Your Medicine. Available at: https://pharmaxo.com/for-patients/medicine/ [Accessed October 2022].
- Sciensus Complex Pharmacy Services. Available at: https://www.sciensus.com/our-services/complex-pharmacy-services/ [Accessed October 2022].
- Hackett, M. Homecare Medicines Towards a Vision For the Future. NHS, Department of Health. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploa... [Accessed October 2022].
